Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
de research portal van de Rijksuniversiteit Groningen Startpagina
Help en veelgestelde vragen
Link wordt geopend op een nieuw tabblad
English
Nederlands
Content zoeken bij de research portal van de Rijksuniversiteit Groningen
Startpagina
Profielen
Onderzoekseenheden
Onderzoeksoutput
Activiteiten
Datasets
Pers/Media
Projecten
Prijzen
Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients
Simone de Vries
, Michael Schaapveld
, Cécile P.M. Janus
, Laurien A. Daniëls
, Eefke J. Petersen
, Richard W.M. van der Maazen
, Josée M. Zijlstra
, Max Beijert
, Marten R. Nijziel
, Karijn M.S. Verschueren
, Leontien C.M. Kremer
, Anna M. van Eggermond
, Pieternella J. Lugtenburg
, Augustinus D.G. Krol
, Judith M. Roesink
,
Wouter J. Plattel
, Dick Johan van Spronsen
,
Gustaaf W. van Imhoff
, Jan Paul de Boer
, Berthe M.P. Aleman
Flora E. van Leeuwen
Toon overzicht 1 andere
Toon minder
Onderzoeksoutput
›
Academic
›
peer review
84
Citaten (Scopus)
176
Downloads (Pure)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Hodgkin Lymphoma
100%
Cause-specific Mortality
100%
Lymphoma Patients
100%
Confidence Interval
60%
Chemotherapy
40%
Excess Mortality
40%
Radiotherapy
30%
Standardized Mortality Ratio
20%
Cumulative Mortality
20%
Hodgkin Lymphoma Survivors
20%
Survivors
10%
High Risk
10%
Patient Selection
10%
Older Individuals
10%
Hazard Ratio
10%
Life Expectancy
10%
Long-term Toxicity
10%
Irradiation
10%
Spleen
10%
Solid Tumors
10%
Cardiovascular Mortality
10%
Cause-specific
10%
Radiotherapy Alone
10%
Risk of Death
10%
Treatment-related Morbidity
10%
Splenectomy
10%
Treatment Impact
10%
Competing Risks
10%
By Stages
10%
Optimal Selection
10%
Chemotherapy Alone
10%
Primary Chemotherapy
10%
Calendar Period
10%
Multicenter Cohort
10%
Infection-related Mortality
10%
Subdistribution Hazard Ratio
10%
Lymphoma Relapse
10%
Immunology and Microbiology
Mortality
100%
Population
66%
Standardized Mortality Ratio
66%
Infectious Disease
33%
Life Expectancy
33%
Nursing and Health Professions
Hodgkin Disease
100%
Confidence Interval
50%
Radiotherapy
33%
Mortality
25%
Population
16%
Hazard Ratio
16%
Standardized Mortality Ratio
16%
Infection
8%
Cardiovascular Disease
8%
Life Expectancy
8%
Splenectomy
8%
Solid Malignant Neoplasm
8%
Medicine and Dentistry
Hodgkin's Lymphoma
100%
Radiation Therapy
33%
Mortality
25%
Population
16%
Hazard Ratio
16%
Standardized Mortality Ratio
16%
Infection
8%
Life Expectancy
8%
Cardiovascular Disease
8%
Solid Malignant Neoplasm
8%
Splenectomy
8%
Pharmacology, Toxicology and Pharmaceutical Science
Hodgkin Disease
100%
Chemotherapy
50%
Mortality
25%
Standardized Mortality Ratio
16%
Infection
8%
Solid Malignant Neoplasm
8%
Cardiovascular Disease
8%
Life Expectancy
8%